Better Science, Better Health: VIB’s Johan Cardoen, An EU Biotech Success Story.

For the first podcast in our series investigating the impact and importance of IP on European biotech and innovation, we have an in-depth discussion with Johan Cardoen of VIB, Gent’s life sciences research institute in Belgium. VIB has been called by Reuters, “part of the success . . . to Belgium’s distinct approach to biotech start-ups.” Given that a VIB spin-out Ablynx was recently acquired by Sanofi for $5 billion dollars, Johan's approach to successful innovation is starting to be noticed in the EU's offices in Brussels, just down the road from Gent, but often a world apart.

Our conversation covers many pressing topics including how VIB has built its well-deserved reputation for creating successful biotech platforms, the brain-drain of maturing biotech companies and strategies to keep them in Europe, the potential impact of IP exemptions like WTO compulsory licenses on biotech companies, why the past GMO debate matters today, and what technologies are currently going to be the next ones to impact the lives of patients.

Better Science, Better Health: VIB’s Johan Cardoen, An EU Biotech Success Story. For the first podcast in our series investigating the impact and importance of IP on European biotech and innovation, we have an in-depth discussion with Johan Cardoen of VIB, Gent’s life sciences research institute in Belgium. VIB has been called by Reuters, “part of the success . . . to Belgium’s distinct approach to biotech start-ups.” Given that a VIB spin-out Ablynx was recently acquired by Sanofi for $5 billion dollars, Johan's approach to successful innovation is starting to be noticed in the EU's offices in Brussels, just down the road from Gent, but often a world apart. Our conversation covers many pressing topics including how VIB has built its well-deserved reputation for creating successful biotech platforms, the brain-drain of maturing biotech companies and strategies to keep them in Europe, the potential impact of IP exemptions like WTO compulsory licenses on biotech companies, why the past GMO debate matters today, and what technologies are currently going to be the next ones to impact the lives of patients.

Duane Schulthess is the CEO of Vital Transformation, host and producer of Vital Health Podcast.  Vital Transformation understands the implications of new medical procedures, technologies and regulations. We measure their impact upon treatment pathways and the biopharma innovation ecosystem in collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and stakeholders.

Duane Schulthess is the CEO of Vital Transformation, host and producer of Vital Health Podcast.  Vital Transformation understands the implications of new medical procedures, technologies and regulations. We measure their impact upon treatment pathways and the biopharma innovation ecosystem in collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and stakeholders.

Duane Schulthess, Managing Director of Vital Tran…

Vital Health Podcast

Better Science, Better Health: VIB’s Johan Cardoe…

Advertisement